Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company focused on small molecule drugs for viral infections, announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The live webcast of the event will be available on Enanta's website, with a replay archived for 60 days. Enanta specializes in developing treatments for various viral infections, including respiratory syncytial virus (RSV), SARS-CoV-2, and hepatitis B virus (HBV). Their research is supported by royalties from hepatitis C virus (HCV) collaborations with AbbVie.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33^rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005380/en/

Media and Investors:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals present at the Oppenheimer 33rd Annual Healthcare Conference?

Enanta Pharmaceuticals will present on March 14, 2023, at 10:00 a.m. ET.

Where can I watch the Enanta Pharmaceuticals conference presentation?

The conference presentation can be watched live on Enanta's website under the 'Events and Presentations' section.

What is Enanta Pharmaceuticals focused on developing?

Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections, including treatments for RSV, SARS-CoV-2, and HBV.

How long will the webcast replay of the Enanta conference be available?

The replay of the webcast will be available for approximately 60 days after the presentation.

What is the stock symbol for Enanta Pharmaceuticals?

The stock symbol for Enanta Pharmaceuticals is ENTA.